MedTrace Logo

Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay

NCT05870592 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-07-11

No results posted yet for this study

Summary

There are numerous Department of Defense (DoD) beneficiaries enrolled in the various lung cancer screening programs across the DoD. This study may enable patients to forego annual CT lung cancer screening or help to predict cancerous nodules without interventional procedures. This is a prospective observational study of sputum cytology using flow cytometry to analyze sputum samples collected from patients in the active military who are undergoing annual lung cancer screening. The primary objective of this study is to analyze the cellular profiles of sputum samples collected from the Acapella® airway assist device in patients at higher risk for lung cancer. The target population are high risk patients for developing lung cancer, age 50-80 with a significant smoking history.

Conditions

Sponsors & Collaborators

  • Brooke Army Medical Center

    collaborator FED

  • bioAffinity Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • Michael J Morris, MD · Brooke Army Medical Center

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-03-31
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870592 on ClinicalTrials.gov